At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 12 enrolled
Drug / intervention
ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells(ALLO-ASC):A Pilot Study
In Brief
A Early Phase 1 clinical trial evaluating ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection for Lateral Epicondylitis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Main purpose of this study is to evaluate efficacy and safety of allogenic adipose-derived mesenchymal stem cells(ALLO-ASC) in treatment of tendon injury. ALLO-ASC will be administrated to the patients with lateral epicondylitis by ultrasonographic guided injection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Epicondylitis
CountriesSouth Korea
CollaboratorsMedical Research Collaborating Center, Seoul, Korea
Timeline
Early Ph 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionJul 2016
Study CompletionApr 2018
TodayJul 2026
First PostedMay 17, 2013
Enrollment StartMay 1, 2013
Primary CompletionJul 1, 2016
Study CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.1 years ago
Interventions
ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injectionbiological